Pharma Mar, S.A. (0RC6.L) Stock Analysis & Winston Score

Pharma Mar is a Spanish biotechnology company that finds medicines in the ocean. It searches for chemical compounds in marine organisms — like sea squirts and fungi — and turns them into cancer-fighting drugs. Its main product is Zepzelca (lurbinectedin), a chemotherapy drug approved to treat a type of lung cancer called small cell lung cancer, which it sells primarily through a partnership with Jazz Pharmaceuticals in the United States. The company earns money through drug sales, licensing deals, and royalties from partners who sell its medicines in different regions. Pharma Mar operates mainly in Europe and the US, and its high gross margin reflects how valuable approved drugs can be once development costs are behind them. Its core competitive advantage is its unique expertise in marine-derived compounds, a niche few other companies pursue. The main risk is its dependence on a small number of drugs — if Zepzelca sales disappoint or a pipeline candidate fails in clinical trials, revenue could fall sharply.